AMRN News and Press, Amarin Corporation plc From 10/26/23

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded research from the landmark REDUCE-IT cardiovascular outcomes trial on the effects of VASCEPA ® /VAZKEPA ® (icosapent ethyl) i...

2023-10-25 12:36:49 ET More on Amarin Amarin Corporation plc (AMRN) Cantor Fitzgerald Annual Amarin's Financial Tug-Of-War: Vascepa Vs. Generics Amarin in deal with Neopharm to sell Vazkepa in Israel Amarin up 6% on deal to sell Vazkepa in South Korea, SE Asi...

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss the Company’s third qua...

2023-09-26 20:12:02 ET Amarin Corporation plc (AMRN) Cantor Fitzgerald Annual Global Healthcare Conference September 26, 2023, 09:55 AM ET CompanyParticipants Patrick Holt - President and CEO Conference Call Participants Carvey Leung - Cantor Fitzgerald ...

2023-09-15 18:58:53 ET Summary Amarin's Q2 2023 earnings declined 15% YoY, citing increased competition and pricing pressures, despite cost-cutting and restructuring. Company maintains liquidity, explores European and global markets as potential growth areas amid U.S. competition....

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer, is scheduled to participate via fireside chat at the 2023 Cantor Global Healthcare Conference. ...

2023-08-17 12:16:09 ET Engaging in the world of low-cost stocks often referred to as penny stocks , is appealing to those looking to capitalize on the potential upsides of the stock market. These stocks, priced below $5, are known for their intrinsic risk. They’re also known for ...

– Dutch Ministry of Health Approves VAZKEPA ® (icosapent ethyl) for National Reimbursement to Reduce the Risk of Cardiovascular Events in Patients with Established Cardiovascular Disease – – Italy’s AIFA Pricing & Reimbursement Com...

-- Agreement Follows Recent Regulatory Approval in Israel of VAZKEPA ® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT –- -- Heart Dise...

-- VAZKEPA® (icosapent ethyl) accepted by the Scottish Medicines Consortium (SMC) for restricted use within NHSScotland, as secondary prevention in adult statin-treated patients at high cardiovascular risk 1 -- -- VAZKEPA® already commercially available in Engl...